This recent transaction increases Srikant Datar’s holding in the company by 11.05% to a total of $3.23 million. In addition to Srikant Datar, 2 other SYK executives reported Buy trades in the last month.
Based on Stryker’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $3.59 billion and quarterly net profit of $466 million. In comparison, last year the company earned revenue of $3.24 billion and had a net profit of $590 million. The company has a one-year high of $223.45 and a one-year low of $144.75. SYK’s market cap is $75.17B and the company has a P/E ratio of 22.27.
One of the top 25 analysts, according to TipRanks.com, recently recommended Buy SYK. Five different firms, including BTIG and Canaccord Genuity, currently also have a Buy rating on the stock.
In the last 30 days, insiders have sold $1M worth of SYK shares and purchased $93.61K worth of SYK shares. The insider sentiment on Stryker has been negative according to 80 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stryker Corp. engages in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems.